NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 233.33 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.90
▲ +0.01 (1.12%)

This chart shows the closing price for MTNB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Matinas BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTNB

Analyst Price Target is $3.00
▲ +233.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Matinas BioPharma in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 233.33% upside from the last price of $0.90.

This chart shows the closing price for MTNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Matinas BioPharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/14/2021HC WainwrightReiterated RatingBuy$3.00
5/11/2021Piper SandlerDowngradeOverweight ➝ Neutral
3/30/2021HC WainwrightReiterated RatingBuy$4.00 ➝ $3.00
2/15/2021AegisReiterated RatingBuy
1/29/2021Maxim GroupReiterated RatingBuy$3.00
1/4/2021Piper SandlerBoost Price TargetOverweight$1.80 ➝ $4.00
11/6/2020Maxim GroupInitiated CoverageBuy$3.00
8/13/2020AegisBoost Price TargetBuy$3.25 ➝ $3.50
8/11/2020HC WainwrightReiterated RatingBuy$4.00
6/2/2020AegisReiterated RatingBuy
5/23/2020Maxim GroupInitiated CoverageBuy$3.00
5/13/2020Maxim GroupReiterated RatingBuy
4/1/2020Maxim GroupInitiated CoverageBuy$3.00
3/6/2020Maxim GroupReiterated RatingBuy
1/26/2020Piper SandlerInitiated CoverageOverweight$3.00
1/23/2020SunTrust BanksInitiated CoverageBuy$3.00
1/9/2020AegisInitiated CoverageBuy$3.50
12/20/2019HC WainwrightReiterated RatingBuy$4.00
9/26/2019Maxim GroupReiterated RatingBuy$3.00
8/14/2019HC WainwrightReiterated RatingBuy$4.00
6/26/2019HC WainwrightReiterated RatingBuy
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$4.00
5/17/2019BTIG ResearchInitiated CoverageBuy$5.00
5/16/2019Maxim GroupReiterated RatingBuy$5.00
2/11/2019Roth CapitalReiterated RatingBuy
2/11/2019Roth CapitalInitiated CoverageBuy$4.75
11/12/2018Maxim GroupBoost Price TargetBuy ➝ Buy$2.00 ➝ $5.00
8/13/2018Maxim GroupLower Price TargetBuy ➝ Buy$3.00 ➝ $2.00
7/10/2018Maxim GroupLower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
5/10/2018Maxim GroupSet Price TargetBuy$4.00
4/23/2018Maxim GroupSet Price TargetBuy$4.00
3/19/2018Maxim GroupSet Price TargetBuy$6.00
8/10/2017Roth CapitalSet Price TargetBuy$9.00
8/8/2017Maxim GroupSet Price TargetBuy$6.00
7/10/2017Roth CapitalReiterated RatingBuy
7/10/2017Roth CapitalInitiated CoverageBuy$9.00
6/26/2017Maxim GroupReiterated RatingBuy$6.00
6/5/2017Maxim GroupSet Price TargetBuy$6.00
5/16/2017Maxim GroupSet Price TargetBuy$6.00
4/3/2017Maxim GroupReiterated RatingBuy$6.00
3/28/2017AegisReiterated RatingBuy ➝ Positive$8.00
3/27/2017Maxim GroupReiterated RatingBuy$6.00
3/2/2017Maxim GroupSet Price TargetBuy$6.00
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2021
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/23/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/21/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Matinas BioPharma logo
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
Read More

Today's Range

Now: $0.90
Low: $0.85
High: $0.92

50 Day Range

MA: N/A

52 Week Range

Now: $0.90
Low: $0.67
High: $1.73

Volume

775,199 shs

Average Volume

738,770 shs

Market Capitalization

$194.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Matinas BioPharma?

The following Wall Street analysts have issued stock ratings on Matinas BioPharma in the last year: Aegis, HC Wainwright, Maxim Group, Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for MTNB.

What is the current price target for Matinas BioPharma?

2 Wall Street analysts have set twelve-month price targets for Matinas BioPharma in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 233.3%. Maxim Group has the highest price target set, predicting MTNB will reach $3.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Matinas BioPharma in the next year.
View the latest price targets for MTNB.

What is the current consensus analyst rating for Matinas BioPharma?

Matinas BioPharma currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTNB will outperform the market and that investors should add to their positions of Matinas BioPharma.
View the latest ratings for MTNB.

How do I contact Matinas BioPharma's investor relations team?

Matinas BioPharma's physical mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company's listed phone number is (908) 443-1860 and its investor relations email address is [email protected] The official website for Matinas BioPharma is www.matinasbiopharma.com.